Total Payments
$607,905
2024 Payments
$24,602
Companies
54
Transactions
997
Medicare Patients
1,266
Medicare Billing
$105,295
Payment Breakdown by Category
Other$431,147 (70.9%)
Travel$100,232 (16.5%)
Consulting$57,785 (9.5%)
Food & Beverage$18,287 (3.0%)
Education$453.88 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $423,900 | 126 | 69.7% |
| Travel and Lodging | $100,232 | 396 | 16.5% |
| Consulting Fee | $57,785 | 15 | 9.5% |
| Food and Beverage | $18,287 | 444 | 3.0% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $6,525 | 3 | 1.1% |
| Grant | $721.74 | 1 | 0.1% |
| Education | $453.88 | 12 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Endo Pharmaceuticals Inc. | $516,884 | 661 | $0 (2024) |
| Avadel Specialty Pharmaceuticals, LLC | $66,160 | 57 | $0 (2019) |
| Endo USA, Inc. | $8,893 | 13 | $0 (2024) |
| Akrimax Pharmaceuticals, LLC | $6,787 | 6 | $0 (2017) |
| Axonics, Inc. | $1,815 | 23 | $0 (2024) |
| Boston Scientific Corporation | $1,739 | 28 | $0 (2024) |
| NeoTract Inc. | $1,047 | 10 | $0 (2020) |
| Janssen Biotech, Inc. | $588.69 | 24 | $0 (2024) |
| Endocare, Inc. | $444.47 | 3 | $0 (2017) |
| Astellas Pharma US Inc | $417.18 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,602 | 74 | Endo Pharmaceuticals Inc. ($14,861) |
| 2023 | $86,904 | 139 | Endo Pharmaceuticals Inc. ($85,862) |
| 2022 | $46,954 | 93 | Endo Pharmaceuticals Inc. ($46,020) |
| 2021 | $22,388 | 63 | Endo Pharmaceuticals Inc. ($19,834) |
| 2020 | $38,815 | 77 | Endo Pharmaceuticals Inc. ($38,348) |
| 2019 | $122,883 | 183 | Endo Pharmaceuticals Inc. ($122,010) |
| 2018 | $201,368 | 259 | Endo Pharmaceuticals Inc. ($135,141) |
| 2017 | $63,991 | 109 | Endo Pharmaceuticals Inc. ($54,807) |
All Payment Transactions
997 individual payment records from CMS Open Payments — Page 1 of 40
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $25.05 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Endo USA, Inc. | XIAFLEX (Biological) | Food and Beverage | In-kind items and services | $20.01 | General |
| Category: UROLOGY | ||||||
| 12/09/2024 | COLOPLAST CORP | Luja Coude (Device) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Continence Care | ||||||
| 12/04/2024 | Olympus America Inc. | iTIND System (Device) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Urology Gynecology | ||||||
| 11/26/2024 | Olympus America Inc. | iTIND System (Device) | Food and Beverage | In-kind items and services | $18.54 | General |
| Category: Urology Gynecology | ||||||
| 11/21/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: UROLOGY | ||||||
| 10/31/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Olympus America Inc. | iTIND System (Device) | Food and Beverage | In-kind items and services | $20.84 | General |
| Category: Urology Gynecology | ||||||
| 10/09/2024 | Myriad Genetic Laboratories, Inc. | PROLARIS (Device) | Food and Beverage | In-kind items and services | $17.27 | General |
| Category: ONCOLOGY | ||||||
| 10/04/2024 | Boston Scientific Corporation | AMS 700 (Device) | Food and Beverage | In-kind items and services | $20.77 | General |
| Category: AMS 700_URO | ||||||
| 10/02/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $28.57 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 09/27/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: ONCOLOGY | ||||||
| 09/24/2024 | Tolmar, Inc. | JATENZO (Drug), ELIGARD | Food and Beverage | Cash or cash equivalent | $17.52 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 09/10/2024 | ConvaTec Inc. | GENTLECATH GLIDE (Device) | Food and Beverage | In-kind items and services | $14.48 | General |
| Category: CONTINENCE CARE | ||||||
| 09/05/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $19.57 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Antares Pharma, Inc. | XYOSTED (Drug) | Food and Beverage | In-kind items and services | $16.95 | General |
| Category: TESTOSTERONE REPLACEMENT THERAPY | ||||||
| 08/27/2024 | Tolmar, Inc. | JATENZO (Drug), ELIGARD | Food and Beverage | Cash or cash equivalent | $14.22 | General |
| Category: HORMONE REPLACEMENT | ||||||
| 08/26/2024 | Endo USA, Inc. | XIAFLEX (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,260.00 | General |
| Category: UROLOGY | ||||||
| 08/26/2024 | Endo USA, Inc. | XIAFLEX (Biological) | Travel and Lodging | Cash or cash equivalent | $135.34 | General |
| Category: UROLOGY | ||||||
| 08/23/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: ONCOLOGY | ||||||
| 08/20/2024 | Endo USA, Inc. | XIAFLEX (Biological) | Food and Beverage | In-kind items and services | $69.91 | General |
| Category: UROLOGY | ||||||
| 08/13/2024 | Endo USA, Inc. | XIAFLEX (Biological) | Food and Beverage | In-kind items and services | $22.52 | General |
| Category: UROLOGY | ||||||
| 08/09/2024 | COLOPLAST CORP | Coloplast TFL Drive (Device) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: Endourology | ||||||
| 08/07/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $24.09 | General |
| Category: ONCOLOGY | ||||||
| 07/30/2024 | Myriad Genetic Laboratories, Inc. | PROLARIS (Device) | Food and Beverage | In-kind items and services | $16.61 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 366 | 461 | $69,274 | $29,008 |
| 2022 | 9 | 355 | 438 | $78,801 | $28,394 |
| 2021 | 9 | 297 | 390 | $84,309 | $31,964 |
| 2020 | 8 | 248 | 292 | $39,209 | $15,929 |
Total Patients
1,266
Total Services
1,581
Medicare Billing
$105,295
Procedure Codes
41
All Medicare Procedures & Services
41 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 101 | 144 | $15,106 | $9,773 | 64.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 88 | 118 | $8,600 | $5,318 | 61.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 48 | 48 | $7,140 | $4,217 | 59.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 20 | 21 | $4,378 | $2,006 | 45.8% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2023 | 29 | 34 | $3,914 | $1,724 | 44.0% |
| 52310 | Simple removal of foreign body, stone, or stent in urethra or bladder using an endoscope | Facility | 2023 | 13 | 14 | $2,652 | $1,615 | 60.9% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2023 | 12 | 13 | $21,546 | $1,595 | 7.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 25 | 30 | $3,016 | $1,376 | 45.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 13 | 17 | $1,880 | $972.56 | 51.7% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2023 | 17 | 22 | $1,042 | $412.50 | 39.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 103 | 158 | $17,904 | $10,504 | 58.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 50 | 50 | $8,305 | $4,352 | 52.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 75 | 86 | $6,473 | $3,932 | 60.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 25 | 25 | $5,004 | $2,594 | 51.8% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2022 | 17 | 17 | $30,018 | $2,033 | 6.8% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2022 | 20 | 27 | $2,738 | $1,504 | 54.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 17 | $2,172 | $885.46 | 40.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 14 | $2,431 | $830.88 | 34.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 12 | 13 | $1,531 | $774.42 | 50.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 13 | 13 | $1,379 | $635.79 | 46.1% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2022 | 14 | 18 | $846.00 | $347.34 | 41.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 107 | 184 | $23,710 | $12,906 | 54.4% |
| 52356 | Crushing of stone in urinary duct (ureter) with stent using an endoscope | Facility | 2021 | 14 | 15 | $12,182 | $4,934 | 40.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 50 | 50 | $9,671 | $4,573 | 47.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 26 | 28 | $5,208 | $2,961 | 56.8% |
About Dr. Richard Bennett, MD
Dr. Richard Bennett, MD is a Urology healthcare provider based in Royal Oak, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/10/2007. The National Provider Identifier (NPI) number assigned to this provider is 1932313574.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Bennett, MD has received a total of $607,905 in payments from pharmaceutical and medical device companies, with $24,602 received in 2024. These payments were reported across 997 transactions from 54 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($423,900).
As a Medicare-enrolled provider, Bennett has provided services to 1,266 Medicare beneficiaries, totaling 1,581 services with total Medicare billing of $105,295. Data is available for 4 years (2020–2023), covering 41 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Royal Oak, MI
- Active Since 05/10/2007
- Last Updated 06/02/2015
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1932313574
Products in Payments
- XIAFLEX (Biological) $520,430
- Noctiva (Drug) $66,160
- STENDRA (Drug) $6,525
- EDEX (Drug) $5,044
- Urolift - UL400 (Device) $990.76
- Bulkamid (Device) $811.49
- GENERAL - ERECTILE DYSFUNCTION (Device) $721.74
- Axonics r-SNM System (Device) $653.45
- ERLEADA (Drug) $593.33
- Endocare Cryocare System (Medical Supply) $444.47
- AMS 700 CXR RTE KIT (Device) $438.16
- Axonics (Device) $350.20
- AVEED (Biological) $293.83
- PROVENGE (Drug) $283.91
- MYRBETRIQ (Drug) $206.79
- GEMTESA (Drug) $196.60
- XTANDI (Drug) $177.76
- Stendra (Drug) $175.14
- JATENZO (Drug) $139.28
- AquaBeam Robotic System (Device) $133.24
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Royal Oak
Dr. Kenneth Peters, Md, MD
Urology — Payments: $26,596
Urology $26,596
Adam Gadzinski, M.d, M.D
Urology — Payments: $18,520
Urology $18,520
Dr. Jason Gilleran, Md, MD
Urology — Payments: $14,239
Urology $14,239
Melissa Fischer, Md, MD
Urology — Payments: $11,402
Urology $11,402
Dr. Hamza Beano, M.d, M.D
Urology — Payments: $8,264
Urology $8,264
Priya Padmanabhan, M.p.h.,M.d, M.P.H.,M.D
Urology — Payments: $7,710
Urology $7,710